Management of non-Hodgkin's lymphomas
Management of non-Hodgkin's lymphomas
复制标题
DOI：
10.1136/pgmj.75.879.2
复制
发表时间：
1999-01-01
影响因子：
5.1
通讯作者：
Lennard, AL
中科院分区：
文献类型：
--
作者：
Mounter, PJ;Lennard, AL
非霍奇金淋巴瘤（NHL）是一组异质性疾病，其特征是淋巴样细胞的恶性增殖。细胞起源相对较好地建立了与淋巴细胞分化的各个阶段相对应的亚型。该术语包括具有非常不同的形态学外观，行为和临床结果的条件的大杂烩。NHL占所有癌症的2.4%，发病率随年龄增长而增加。最常见的临床表现是进行性淋巴结病，尽管淋巴结表现也占很大比例。临床表现从良性、无痛性病程到快速进展性疾病;预后从数周至数年不等。治疗也相应地多样化，从“观察等待”到高剂量化疗和骨髓干细胞移植。治愈是可能的，在越来越多的患者，目前的兴趣在于确定患者的高风险疾病，需要使用强化治疗方案。
The non-Hodgkin's lymphomas (NHL) are a heterogenous group of disorders characterised by malignant proliferation of lymphoid cells. The cellular origin is relatively well established with subtypes corresponding to the various stages of lymphocyte differentiation. The term encompasses a hotchpotch of conditions with very different morphological appearance, behaviour and clinical outcome. NHL comprise 2.4% of all cancers, with incidence increasing with age. The commonest presentation is with progressive lymphadenopathy, though extranodal manifestations are present in a significant proportion. The clinical behaviour ranges from a benign, indolent course to rapidly progressive disease; prognosis varies from weeks to many years. Treatment is correspondingly diverse, from 'watchful waiting' to high-dose chemotherapy with bone marrow stem cell transplantation. Cure is possible in an increasing number of patients and much interest currently lies in identifying patients with high-risk disease necessitating the use of intensive treatment regimens.